WST Free cash flow
Free cash flow at West Pharmaceutical Services rose to $469M in fiscal 2025, the highest in the 5 years reported, from $276M in 2024.
Not a GAAP measure. Derived here as operating cash flow less capital expenditure, both as filed; the arithmetic is shown in the table.
SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities + us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · EDGAR CompanyFacts · CIK 105770 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|
| FY2025 | $755M | −$286M | $469M |
| FY2024 | $653M | −$377M | $276M |
| FY2023 | $776M | −$362M | $414M |
| FY2022 | $724M | −$285M | $439M |
| FY2021 | $584M | −$253M | $331M |
More SAME DATA, OTHER VIEWS
Free cash flow across coverage → · WST company view →
Revenue · Net income · Operating cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.